Schrödinger (NASDAQ:SDGR) said Monday it has signed an expanded, three-year software agreement with Eli Lilly, building on its collaboration since 2022. The agreement provides Lilly with large-scale access to Schrödinger’s full suite of technologies to enable and accelerate all stages of drug discovery.

Schrödinger（NASDAQ:SDGR）周一表示，公司已与礼来公司（EliLilly）签署了一份为期三年的扩展软件协议，该协议建立在自2022年以来的合作基础上。该协议为礼来提供了大规模使用薛定谔全套技术的机会，以实现和加速药物发现的所有阶段。

Looking ahead, the company said it expects to advance the Phase 1 study of SGR-1505 in advanced B cell malignancies to enable initial data release in late 2024 or 2025, and advance the Phase 1 study of SGR-2921 in patients with AML/MDS to enable initial data release in late 2024 or 2025. The company also plans on submitting the IND application for SGR-3515 in the first half of 2024 and initiating a Phase 1 study in 2024, and additionally expects to advance the discovery-stage proprietary pipeline to enable an additional IND submission in 2025, among other things.

展望未来，该公司表示，预计将推进SGR-1505在晚期B细胞恶性肿瘤中的第一阶段研究，以便在2024年末或2025年发布初始数据，并推进SGR-2921在AML/MDS患者中的第一阶段研究，以便在2024年末或2025年发布初始数据。该公司还计划在2024年上半年提交SGR-3515的IND申请，并在2024年启动第一阶段研究，此外，预计将推进发现阶段专有管道，以便在2025年提交额外的IND。

Press Release. More on Schrödinger Schrodinger Appears To Be Losing Momentum Schrodinger: Attractive Risk-Reward Schrödinger Q3 2023 Earnings Call Transcript KeyBanc sees opportunity in tech-enabled drug discovery stocks Schrödinger GAAP EPS of -$0.86 misses by $0.17, revenue of $42.6M beats by $4.75M .

新闻稿。关于薛定谔的更多信息薛定谔似乎正在失去动力薛定谔：有吸引力的风险回报薛定谔2023年第三季度收益通话记录KeyBanc认为科技型药物发现股票的机会薛定谔GAAP每股收益减少了0.17美元，减少了0.86美元，收入4260万美元，减少了475万美元。